Alx Research Development from 2010 to 2026

ALXO Stock  USD 1.74  0.17  10.83%   
Alx Oncology Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to drop to about 74.4 M. During the period from 2010 to 2026, Alx Oncology Research Development quarterly data regression pattern had sample variance of 2351 T and median of  11,270,000. View All Fundamentals
 
Research Development  
First Reported
2019-03-31
Previous Quarter
18 M
Current Value
17.4 M
Quarterly Volatility
12 M
 
Covid
 
Interest Hikes
Check Alx Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alx Oncology's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.2 M or Depreciation And Amortization of 1.1 M, as well as many indicators such as Price To Sales Ratio of 2.7 K, Dividend Yield of 0.0 or PTB Ratio of 0.72. Alx financial statements analysis is a perfect complement when working with Alx Oncology Valuation or Volatility modules.
  
Build AI portfolio with Alx Stock
Check out the analysis of Alx Oncology Correlation against competitors.
Evaluating Alx Oncology's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Alx Oncology Holdings's fundamental strength.

Latest Alx Oncology's Research Development Growth Pattern

Below is the plot of the Research Development of Alx Oncology Holdings over the last few years. It is Alx Oncology's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alx Oncology's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Alx Research Development Regression Statistics

Arithmetic Mean45,390,337
Geometric Mean26,264,669
Coefficient Of Variation106.82
Mean Deviation41,481,966
Median11,270,000
Standard Deviation48,486,964
Sample Variance2351T
Range130.5M
R-Value0.81
Mean Square Error853.7T
R-Squared0.66
Significance0.000075
Slope7,798,059
Total Sum of Squares37615.8T

Alx Research Development History

202674.4 M
2025133.8 M
2024116.4 M
2023141.8 M
202298.4 M
202160.2 M
202029 M

About Alx Oncology Financial Statements

Alx Oncology investors utilize fundamental indicators, such as Research Development, to predict how Alx Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development133.8 M74.4 M

Pair Trading with Alx Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Alx Stock

  0.5MOLN Molecular PartnersPairCorr
  0.36CRDF Cardiff Oncology Buyout TrendPairCorr
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out the analysis of Alx Oncology Correlation against competitors.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Will Biotechnology sector continue expanding? Could Alx diversify its offerings? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alx Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.01)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.51)
Return On Equity
(1.19)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Alx Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alx Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Alx Oncology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.